Artal Group S.A. 89bio, Inc. Transaction History
Artal Group S.A.
- $214 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding ETNB
# of Institutions
163Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$136 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$127 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$71.6 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$66.1 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$62.9 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $417M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...